Evidence-Based Incorporation of Serum Sodium Concentration Into MELD
Scott W. Biggins(University of Colorado Denver), Göran Klintmalm(Mayo Clinic), Norah A. Terrault(University of Southern California), Thomas D. Schiano(Icahn School of Medicine at Mount Sinai), V Balan(Mayo Clinic in Arizona), Walter K. Kremers(Mayo Clinic), Sammy Saab(Mount Sinai Medical Center), W. Ray Kim(Mayo Clinic in Arizona), Russell H. Wiesner(Mayo Clinic in Arizona), Patrick S. Kamath(Mayo Clinic in Arizona), Joanne Benson(Mayo Clinic in Arizona), Terry M. Therneau(Mayo Clinic)
Cited by 777
Related Papers
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Global burden of liver disease: 2023 update
|Journal of Hepatology|2023|1.9k
Hyponatremia and Mortality among Patients on the Liver-Transplant Waiting List
|New England Journal of Medicine|2008|1.5k